image
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of pharmacological inhibitors
with a unique mechanism of action
Signaling Specific inhibitors
of the CB1 (CB1-SSi)
Targeting disease states of the brain while preserving normal behavior
AEF0117 for cannabis related disorders
AEF0217 for the treatment of cognitive deficits
Aelis Farma’s Mission
To combine the scientific breakthrough of CB1 with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
Pier Vincenzo Piazza, CEO
Latest News
The European Commission grants €6 million to the ICOD project for the development of AEF0217 (Aelis Farma) to treat cognitive deficits in Down syndrome
April 2021
+
Aelis Farma announces good results from its first administration in humans for AEF0217, its first drug candidate for the treatment of cognitive disorders in ...
November 2021
+